Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 10,900 Shares

Key Points

• Ryan Cohlhepp, COO of Bicara Therapeutics, sold 10,900 shares at an average price of $18.06, reducing his stake by 5.10% in the company.
• Bicara's stock has shown significant volatility, with a fifty-two week range between $7.80 and $28.09, and is currently trading at $18.00.
• Analysts maintain a generally positive outlook on Bicara Therapeutics, with a consensus target price of $31.86 and multiple firms rating the stock as "buy" or "outperform."

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 10,900 shares of Bicara Therapeutics stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $18.06, for a total transaction of $196,854.00. Following the completion of the sale, the chief operating officer directly owned 202,641 shares of the company's stock, valued at approximately $3,659,696.46. The trade was a 5.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Ryan Cohlhepp also recently made the following trade(s):

• On Monday, October 6th, Ryan Cohlhepp sold 39,600 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.06, for a total transaction of $715,176.00.

Bicara Therapeutics Price Performance

Shares of BCAX stock traded down $0.17 on Wednesday, hitting $18.00. The company's stock had a trading volume of 514,631 shares, compared to its average volume of 579,256. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $28.09. The firm's fifty day moving average price is $12.09 and its 200-day moving average price is $11.76. The stock has a market capitalization of $982.98 million and a price-to-earnings ratio of -5.68.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.04. Analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BCAX. Piper Sandler began coverage on shares of Bicara Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $36.00 target price on the stock. HC Wainwright dropped their target price on shares of Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. Wedbush reiterated an "outperform" rating and issued a $30.00 target price on shares of Bicara Therapeutics in a report on Tuesday, August 12th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Bicara Therapeutics in a report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $31.86.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its position in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock valued at $44,000 after buying an additional 3,866 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Bicara Therapeutics by 80.6% during the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company's stock valued at $46,450,000 after buying an additional 2,231,025 shares during the last quarter. Bank of America Corp DE raised its position in shares of Bicara Therapeutics by 2,351.0% during the second quarter. Bank of America Corp DE now owns 451,228 shares of the company's stock valued at $4,192,000 after buying an additional 432,818 shares during the last quarter. Ameriprise Financial Inc. bought a new stake in Bicara Therapeutics in the second quarter valued at about $149,000. Finally, Jane Street Group LLC bought a new stake in Bicara Therapeutics in the second quarter valued at about $266,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.